Transcriptional and post-transcriptional regulation of cGMP-dependent protein kinase (PKG-I): Pathophysiological significance

Cardiovascular Research

Volumn 97, Issue 2, 2013, Pages 200-207

  Sellak, Hassan ^a   Choi, Chung Sik ^a   Dey, Nupur B ^a   Lincoln, Thomas M ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

cGMP dependent protein kinase; Gene; mRNA stability; Post transcription; Regulation; Transcription; Ubiquitination; Vascular smooth muscle cells

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE 1; CYTOKINE; GROWTH FACTOR; MESSENGER RNA; NITRIC OXIDE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; BLOOD VESSEL INJURY; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; VASCULAR SMOOTH MUSCLE;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; ANIMALS; CYCLIC GMP-DEPENDENT PROTEIN KINASE TYPE I; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; TRANSCRIPTION, GENETIC;

EID: 84872538931     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs327     Document Type: Review

References (113)

1. Lincoln TM, Hall CL, Park CR, Corbin JD. Guanosine 3′:5′- cyclic monophosphate binding proteins in rat tissues. Proc Natl Acad Sci USA 1976;73:2559-2563.
2. Kuo JF, Kuo WN, Shoji M, Davis CW, Seery VL, Donnelly TE Jr. Purification and general properties of guanosine 3′:5′-monophosphate-dependent protein kinase from guinea pig fetal lung. J Biol Chem 1976;251:1759-1766.
3. Light DB, Corbin JD, Stanton BA. Dual ion-channel regulation by cyclic GMP and cyclic GMP-dependent protein kinase. Nature 1990;344:336-339.
4. Beavo JA, Hardman JG, Sutherland EW. Hydrolysis of cyclic guanosine and adenosine 3′,5′-monophosphates by rat and bovine tissues. J Biol Chem 1970;245: 5649-5655.
5. Pfeifer A, Klatt P, Massberg S, Ny L, Sausbier M, Hirneiss C et al. Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J 1998;11:3045-3051.
6. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res 2003;93:907-916.
7. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006;86:1-23.
8. Zhao YD, Cai L, Mirza MK, Huang X, Geenen DL, Zhao YY. Protein kinase G-I deficiency induces pulmonary hypertension through Rho A/Rho kinase activation. Am J Pathol 2012;180:2268-2275.
9. Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F, Walter U. Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3′,5′-cyclic monophosphate-dependent protein kinase. Circulation 2003;108:2172-2183.
10. Chiche JD, Schlutsmeyer SM, Bloch DB, de la Monte SM, Roberts JD Jr, Filippov G et al. Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the antiproliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem 1998;273: 34263-34271.
11. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M et al. Stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003;12:77-86.
12. Choi C, Sellak H, Brown FM, Lincoln TM. cGMP-dependent protein kinase and the regulation of vascular smooth muscle cell gene expression: possible involvement of Elk-1 sumoylation. Am J Physiol Heart Circ Physiol 2010;299:H1660-H1670.
13. Lincoln TM, Wu X, Sellak H, Dey N, Choi CS. Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. Front Biosci 2006;11:356-367.
14. Pilz RB, Casteel DE. Regulation of gene expression by cyclic GMP. Circ Res 2003;93: 1034-1046.
15. Lincoln TM, Dey N, Sellak H. cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol 2001;91:1421-1430.
16. Idriss SD, Gudi T, Casteel DE, Kharitonov VG, Pilz RB, Boss GR. Nitric oxide regulation of gene transcription via soluble guanylate cyclase and type I cGMP-dependent protein kinase. J Biol Chem 1999;274:9489-9493.
17. Gudi T, Lohmann SM, Pilz RB. Regulation of gene expression by cyclic GMP-dependent protein kinase requires nuclear translocation of the kinase: identification of a nuclear localization signal. Mol Cell Biol 1997;17:5244-5254.
18. Haby C, Lisovoski F, Aunis D, Zwiller J. Stimulation of the cyclic GMP pathway by NO induces expression of the immediate early genes c-fos and junB in PC12 cells. J Neurochem 1994;62:496-501.
19. Tamura N, Itoh H, Ogawa Y, Nakagawa O, Harada M, Chun TH et al. cDNA cloning and gene expression of human type Ia cGMP-dependent protein kinase. Hypertension 1996;27:552-557.
20. Kuo JF. Guanosine 3′:5′-monophosphate-dependent protein kinases in mammalian tissues. Proc Natl Acad Sci USA 1974;71:4037-4041.
21. Cornwell TL, Soff GA, Traynor AE, Lincoln TM. Regulation of the expression of cyclic GMP-dependent protein kinase by cell density in vascular smooth muscle cells. J Vasc Res 1994;31:330-337.
22. Draijer R, Vaandraager AR, Nolte C, De Jonge HG,Walter U, Van Hinsbergh VWM. Expression of cGMP-dependent protein kinase I and phosphorylation of its substrate, vasodilator-stimulated phosphoprotein, in human endothelial cells of different origin. Circ Res 1995;77:897-905.
23. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010; 62:525-563.
24. Schlossmann J, Desch M. IRAG and novel PKG targeting in the cardiovascular system. Am J Physiol Heart Circ Physiol 2011;301:H672-H682.
25. Hofmann F, Bernhard D, Lukowski R, Weinmeister P. cGMP-dependent protein kinase modulators. Handb Exp Pharmacol 2009;191:409-421.
26. Kemp-Harper B, Schmidt HH. cGMP in the vasculature. Handb Exp Pharmacol 2009; 191:447-467.
27. Persson K, Pandita RK, Aszodi A, Ahmad M, Pfeifer A, Fassler R et al. Functional characteristics of urinary tract smooth muscles in mice lacking cGMP protein kinase type I. Am J Physiol Regul Integr Comp Physiol 2000;279:R1112-R1120.
28. Ny L, Pfeifer A, Aszodi A, Ahmad M, Alm P, Hedlund P et al. Impaired relaxation of stomach smooth muscle in mice lacking cyclic GMP-dependent protein kinase I. Br J Pharmacol 2000;129:395-401.
29. Hedlund P, Aszodi A, Pfeifer A, Alm P, Hofmann F, Ahmad M et al. Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. Proc Natl Acad Sci USA 2000;97: 2349-2354.
30. Halbrügge M, Walter U. Purification of vasodilator regulated phosphoprotein from human platelets. Eur J Biochem 1989;185:41-45.
31. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 2009;122:216-238.
32. Kass DA. Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials. Curr Heart Fail Rep 2012;9:192-199.
33. Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail 2011;4:8-17.
34. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res 2009;81:519-527.
35. Wollert KC, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E et al. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 2002;39:87-92.
36. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 2002;99:11363-11368.
37. Lincoln TM, Komalavilas P, Boerth NJ, MacMillan-Crow LA, Cornwell TL. cGMP signaling through cAMP-and cGMP-dependent protein kinases. Adv Pharmacol 1995;34: 305-322.
38. Sausbier M, Schubert R, Voigt V, Hirneiss C, Pfeifer A, Korth M et al. Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res 2000;87:825-830.
39. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J Biol Chem 2005; 280:1-4.
40. Walter U. Physiological role of cGMP and cGMP-dependent protein kinase in the cardiovascular system. Rev Physiol Biochem Pharmacol 1989;113:41-88.
41. Orstavik S, Sandberg M, Bérubé D, Natarajan V, Simard J,Walter U et al. Localization of the human gene for the type I cyclic GMP-dependent protein kinase to chromosome 10. Cytogenet Cell Genet 1992;59:270-273.
42. Butt E, Geiger J, Jarchau T, Lohmann SM, Walter U. The cGMP-dependent protein kinase: gene, protein, and function. Neurochem Res 1993;18:27-42.
43. Walter U. Physiological role of cGMP and cGMP-dependent protein kinase in cardiovascular system. Rev Physiol Biochem Pharmacol 1989;113:42-88.
44. Sandberg M, Natarajan V, Ronander I, Kalderon D, Walter U, Lohmann SM et al. Molecular cloning and predicted full-legth amino acid sequence of the type IB isozyme of cGMP-dependent protein kinase from human placenta. FEBS Lett 1989; 255:321-329.
45. Wolf L, Francis SH, Corbin JD. Characterization of a novel isozyme of cGMP-dependent protein kinase from bovine aorta. J Biol Chem 1989;364: 4157-4172.
46. Wernet W, Flockerzi V, Hofmann F. The cDNA of the two isoforms of bovine cGMP-dependent protein kinase from bovine aorta. FEBS Lett 1989;251:191-196.
47. Francis SH, Woodford TA, Wolfe L, Corbin JD. Types Ialpha and Ibeta isozymes of cGMP-dependent protein kinase: alternative mRNA splicing may produce different inhibitory domains. Second Messengers Phosphoproteins 1989;12:301-310.
48. Orstavik S, Natarajan V, Taskén K, Jahnsen T, Sandberg M. Characterization of the human gene encoding the type Ia and type Ib cGMP-dependent protein kinase (PRKG1). Genomics 1997;42:311-318.
49. Sellak H, Yang X, Cao X, Cornwell T, Soff GA, Lincoln TM. Sp1 transcription factor as a molecular target for nitric oxide-and cyclic nucleotide-mediated suppression of cGMP-dependent protein kinase-Ia expression in vascular smooth muscle cells. Circ Res 2002;90:405-412.
50. Sellak H, Choi CS, Browner N, Lincoln TM. Upstream stimulatory factors (USF-1/USF-2) regulate human cGMP-dependent protein kinase I gene expression in vascular smooth muscle cells. J Biol Chem 2005;280:18425-18433.
51. Zeng Y, Zhuang S, Gloddek J, Tseng CC, Boss GR, Pilz RB. Regulation of cGMP-dependent protein kinase expression by Rho and Kruppel-like transcription factor-4. J Biol Chem 2006;281:16951-16961.
52. Koutsodontis G, Moustakas A, Kardassis D. The role of Sp1 family members, the proximal GC-rich motifs and the upstream enhancer region in the regulation of the human cell cycle inhibitor p21WAF-1/Cip1 gene promoter. Biochemistry 2002; 41:12771-12784.
53. Ai W, Liu Y, Langlois M, Wang TC. Krüppel-like factor 4 (KLF4) represses histidine decarboxylase gene expression through an upstream Sp1 site and downstream gastrin responsive elements. J Biol Chem 2004;279:8684-8693.
54. Hou Y, Ye RD, Browning DD. Activation of the small GTPase Rac1 by cGMP-dependent protein kinase. Cell Signal 2004;16:1061-1069.
55. Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 2003;278:9472-9480.
56. Sawada N, Itoh H, Yamashita J, Doi K, Inoue M, Masatsugu K et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun 2001;280:798-805.
57. Bois PRJ, Brochard VF, Salin-Cantegrel AVA, Cleveland JL, Grosveld GC. FoxO1a-cyclic GMP-dependent kinase I interactions orchestrate myoblast fusion. Mol Cell Biol 2005;25:7645-7656.
58. Li X, Jiang Y,Wang Z, Liu G, Hutz RJ, Liu Wet al. Regulation of FoxO1 transcription factor by nitric oxide and cyclic GMP in cultured rat granulosa cells. Zoolog Sci 2005; 22:1339-1346.
59. Tedeschi A, Nguyen T, Steele SU, Feil S, Naumann U, Feil R et al. The tumor suppressor p53 transcriptionally regulates PKG-I expression during neuronal maturation and is required for cGMP-dependent growth cone collapse. J Neurosci 2009;29: 15155-15160.
60. Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P et al. Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem 2001;276:43604-43610.
61. Xiao J, Lin H, Luo X, Luo X, Wang Z. miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J 2011;30: 524-532.
62. Borgan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 2001; 11:66-75.
63. Birsoy K, Chen Z, Friedman J. Transcriptional regulation of adipogenesis by KLF4. Cell Metab 2008;7:339-347.
64. Lee J-W, Chen H, Pullikotil P, Quon MJ. Protein kinase A-a directly phosphorylates FoxO1 in vascular endothelial cells to regulate expression of vascular cellular adhesion molecule-1 mRNA. J Biol Chem 2011;286:6423-6432.
65. Sayasith K, Lussier JG, Sirois J. Role of upstream stimulatory factor phosphorylation in the regulation of the prostaglandin G/H synthase-2 promoter in granulosa cells. J Biol Chem 2005;280:28885-28893.
66. Wang S, Wang W, Wesley R, Danner RL. A Sp1 binding site of the tumor necrosis factor a promoter functions as a nitric oxide response element. J Biol Chem 1999; 274:33190-33193.
67. Casteel DE, Zhuang S, Gudi T, Tang J, Vuica M, Desiderio S et al. cGMP-dependent protein kinase Ib physically and functionally interacts with the transcriptional regulator TFII-I. J Biol Chem 2002;277:32003-32014.
68. Gudi T, Casteel DE, Vinson C, Boss GR, Pilz RB. NO activation of fos promoter elements requires nuclear translocation of G-kinase I and CREB phosphorylation but is independent of MAP kinase activation. Oncogene 2000;19:6324-6333.
69. He B, Weber GF. Phosphorylation of NF-kB proteins by cyclic GMP-dependent kinase. A noncanonical pathway to NF-kB activation. Eur J Biochem 2003;270: 2174-2185.
70. Esteve L, Lutz P, Thiriet N, Revel M, Aunis D, Zwiller J. Cyclic GMP-dependent protein kinase potentiates serotonin-induced Egr-1 binding activity in PC12 cells. Cell Signal 2001;13:425-432.
71. Pilz R, Suhasini M, Idrissi S, Meinkoth JL, Boss GR. Nitric oxide and cGMP analogs activate transcription from AP-1-responsive promoters in mammalian cells. FASEB J 1995;9:552-558.
72. Ross J. mRNA stability in mammalian cells. Microbiol Rev 1995;59:423-450.
73. Sellak H, Lincoln TM, Choi CS. Stabilization of cGMP-dependent protein kinase G (PKG) expression in vascular smooth muscle cells: contribution of 3′UTR of its mRNA. J Biochem 2011;149:433-441.
74. Browner NC, Sellak H, Lincoln TM. Downregulation of cGMP-dependent protein kinase expression by inflammatory cytokines in vascular smooth muscle cells. Am J Physiol Cell Physiol 2004;287:C88-C96.
75. Boerth NJ, Dey NB, Cornwell TL, Lincoln TM. Cyclic GMP-dependent protein kinase regulates vascular smooth muscle cell phenotype. J Vasc Res 1997;34: 245-259.
76. Lee HW, Smith L, Pettit GR, Vinitsky A, Smith JB. Ubiquitination of protein kinase C-a and degradation by the proteasome. J Biol Chem 1996;271:20973-20976.
77. Richardson JM, Howard P, Massa JS, Maurer RA. Post-transcriptional regulation of cAMP-dependent protein kinase activity by cAMP in GH3 pituitary tumor cells. Evidence for increased degradation of catalytic subunit in the presence of cAMP. J Biol Chem 1990;265:13635-13640.
78. Dey NB, Busch JL, Francis SH, Corbin JD, Lincoln TM. Cyclic GMP specifically suppresses Type 1a cGMP-dependent protein kinase expression by ubiquitination. Cell Signal 2009;21:859-866.
79. Busch JL, Bessay EP, Francis SH, Corbin JD. A conserved serine juxtaposed to the pseudosubstrate site of type I cGMP-dependent protein kinase contributes strongly to autoinhibition and lower cGMP affinity. J Biol Chem 2002;277:34048-34054.
80. Gao Y, Dhanakoti S, Trevino EM, Wang X, Sander FC, Portugal AD et al. Role of cGMP-dependent protein kinase in development of tolerance to nitric oxide in pulmonary veins of newborn lambs. Am J Physiol Lung Cell Mol Physiol 2004;286: L786-L792.
81. Ramchandran R, Pilipenko E, Bach L, Raghavan A, Reddy SP, Raj JU. Hypoxic regulation of pulmonary vascular smooth muscle cyclic guanosine monophosphatedependent kinase by the ubiquitin conjugating system. Am J Respir Cell Mol Biol 2012;46:323-330.
82. Smith JA, Francis SH, Walsh KA, Kumar S, Corbin JD. Autophosphorylation of type Ib cGMP-dependent protein kinase increases basal catalytic activity and enhances allosteric activation by cGMP or cAMP. J Biol Chem 1996;271:20756- 20762.
83. Francis SH, Smith JA, Colbran JL, Grimes K, Walsh KA, Kumar S et al. Arginine 75 in the pseudosubstrate sequence of type Ib cGMP-dependent protein kinase is critical for autoinhibition, although autophosphorylated serine 63 is outside this sequence. J Biol Chem 1996;271:20748-20755.
84. Melichar VO, Behr-Roussel D, Zabel U, Uttenthal LO, Rodrigo J, Rupin A et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 2004;101: 16671-16676.
85. Sinnaeve P, Chiche JD, Gillijns H, Van Pelt N, Wirthlin D, Van DeWerf F et al. Overexpression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation 2002;105:2911-2916.
86. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004;84:767-801.
87. deBois D, O'Brien ER. The intima soil for atherosclerosis and restenosis. Circ Res 1995;77:445-465.
88. Chyu KY, Dimayuga P, Zhu J, Nilsson J, Kaul S, Shah PK et al. Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. Circ Res 1999;85:1192-1198.
89. Von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137-1141.
90. Beasley D, Cooper A. Constitutive expression of interleukin-1a precursor promotes human vascular smooth muscle cell proliferation. Am J Physiol 1999;276: H901-H912.
91. Taylor AM, McNamara CA. Regulation of vascular smooth muscle cell growth: targeting the final common pathway. Arterioscler Thromb Vasc Biol 2003;23:1717-1720.
92. Anwar A, Zahid AA, Scheidegger KJ, Brink M, Delafontaine P. Tumor necrosis factor-a regulates insulin-like growth factor-1 and insulin-like growth factor binding protein-3 expression in vascular smooth muscle. Circulation 2002;105: 1220-1225.
93. Taylor MS, Okwuchukwuasanya C, Nicki C, Tegge W, Brayden JE, Dostmann WRG. Inhibition of cGMP-dependent protein kinase by the cell-permeable peptide DT-2 reveals a novel mechanism of vasoregulation. Mol Pharmacol 2004;65:1111-1119.
94. Zhou Z, Sayed N, Pyriochou A, Roussos C, Fulton D, Beeves A et al. Protein kinase G phosphorylates soluble guanylyl cyclase on serine 64 and inhibits its activity. Arterioscler Thromb Vasc Biol 2008;28:1803-1810.
95. John TA, Ibe BO, Raj JU. Regulation of endothelial nitric oxide synthase: involvement of protein kinase G 1b, serine 116 phosphorylation and lipid structures. Clin Exp Pharmacol Physiol 2008;35:148-158.
96. Dou D, Zheng X, Qin X, Qi H, Liu L, Raj JU et al. Role of cGMP-dependent protein kinase in development of tolerance to nitroglycerine in porcine coronary arteries. Br J Pharmacol 2008;153:497-507.
97. Zhuang D, Balani P, Pu Q, Thakran S, Hassid A. Suppression of PKG by PDGF or nitric oxide in differentiated aortic smooth muscle cells: obligatory role of protein tyrosine phosphatase 1B. Am J Physiol Heart Circ Physiol 2011;300:H57-H63.
98. Soff GA, Cornwell TL, Cundiff DL, Gately S, Lincoln TM. Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. J Clin Invest 1997;100:2580-2587.
99. Jacob A, Smolenski A, Lohmann SM, Begum N. MKP-1 expression and stabilization and cGK Ia prevent diabetes-associated abnormalities in VSMC migration. Am J Physiol Cell Physiol 2004;287:C1077-C1086.
100. Li Y, Gao Y, Zeng D. Atorvastatin inhibits collar-induced intimal thickening of rat carotid artery: effect on C-type natriuretic peptide expression. Mol Med Report 2012;5:675-679.
101. Anderson PG, Boerth NJ, Liu M, McNamara DB, Cornwell TL, Lincoln TM. Cyclic GMP-dependent protein kinase expression in coronary arterial smooth muscle in response to balloon catheter injury. Arterioscler Thromb Vasc Biol 2000;20: 2192-2197.
102. Resnik E, Herron J, Keck M, Sukovich D, Linden B, Cornfield DN. Chronic intrauterine pulmonary hypertension selectively modifies pulmonary artery smooth muscle cell gene expression. Am J Physiol Lung Cell Mol Physiol 2006;290:L426-L433.
103. Lin CS, Liu X, Tu R, Chow S, Lue TF. Age-related decrease of protein kinase G activation in vascular smooth muscle cells. Biochem Biophys Res Commun 2001;287: 244-248.
104. Yamashita T, Kawashima S, Ohashi Y, Ozaki M, Rikitake Y, Inoue N et al. Mechanisms of reduced nitric oxide/cGMP-mediated vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. Hypertension 2000;36:97-102.
105. Chang S, Hypolite JA, Velez M, Changolkar A,Wein AJ, Chacko S et al. Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. Am J Physiol Regul Integr Comp Physiol 2004;287: R950-R960.
106. Perkins WJ, Warner D, Jones KA. Prolonged treatment of porcine pulmonary artery with nitric oxide decreases cGMP sensitivity and cGMP-dependent protein kinase specific activity. Am J Physiol Lung Cell Mol Physiol 2009;296:L121-L129.
107. Bachiller PR, Nakanishi H, Roberts JD. Transforming growth factor-b modulates the expression of nitric oxide signaling enzymes in the injured developing lung and in vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2010;298:L324-L334.
108. Gao Y, Dhanakoti S, Trevino EM, Sander FC, Portugal AM, Raj JU. Effect of oxygen on cyclic GMP-dependent protein kinase-mediated relaxation in ovine fetal pulmonary arteries and veins. Am J Physiol Lung Cell Mol Physiol 2003;285:L611-L618.
109. Ruetten H, Zabel U, Linz W, Schmidt HH. Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res 1999;85: 534-541.
110. Li Y, Tong X, Maimaitiyiming H, Clemons K, Cao J-M, Wang S. Overexpression of cGMP-dependent protein kinase I (PKG-I) attenuates ischemia-reperfusion-induced kidney injury. Am J Physiol Renal Physiol 2012;302:F561-F570.
111. Zhou W, Dasgupta C, Negash S, Raj JU. Modulation of pulmonary vascular smooth muscle cell phenotype in hypoxia: role of cGMP-dependent protein kinase. Am J Physiol Lung Cell Mol Physiol 2007;292:L1459-L1466.
112. Liu S, Ma X, Gong M, Shi L, Lincoln T, Wang S. Glucose downregulation of cGMP-dependent protein kinase I expression in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Free Radic Biol Med 2007;42:852-863.
113. Wang S, Li Y. Expression of constitutively active cGMP-dependent protein kinase inhibits glucose-induced vascular smooth muscle cell proliferation. Am J Physiol Heart Circ Physiol 2009;297:H2075-H2083.